Aster DM Quality Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,829 Cr +136.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AD

Aster DM Quality

Q4 FY26Healthcare Services

Aster DM Quality Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,182Cr
+18.2% YoY
−0.3% QoQ
Net profit
₹154Cr
+79.1% YoY
+161% QoQ
Margin
19%
+1 pp YoY
+2 pp QoQ
Price₹762
Market cap₹66.4K Cr
P/E183.9

The short version

QCIL registered 17% revenue growth in FY26, supported by 7% IP volume and 10% OP volume growth. QCIL expects continued growth with FY26 registering 17% revenue growth and 24.1% EBITDA growth, indicating strong momentum.

From Aster DM Quality's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • QCIL registered 17% revenue growth in FY26, supported by 7% IP volume and 10% OP volume growth.
  • Mature units grew revenue by 13.5% YoY with 20.7% EBITDA growth and margin expansion to 33.2%.
  • Focus units showed 21% revenue growth and 66.6% EBITDA growth with EBITDA margin expanding by 422 bps to 15.4%.
  • Emerging units delivered 62.4% revenue growth YoY and 44% QoQ EBITDA growth, with margins improving to 17.9%.
  • Oncology volumes expected to significantly grow over next two years, particularly in mature hospitals.
  • Expansion plans involve adding around 1,500 beds through brownfield and 200 beds via greenfield projects over next few years.
  • Per bed capex is INR 0.8-1.1 crore (brownfield) and INR 1.5-1.6 crore (greenfield), supporting growth in capacity and capabilities.

2 more points from Aster DM Quality's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aster DM Quality said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For the year ended March 31, 2026, capital expenditure was INR 549 crores, with 45% towards expansion projects.
  • Planned addition of ~2,500 beds over the next four years at a cost of INR 2,700 crores; INR 350 crores invested till March 2026.
  • QCIL expansion budget: ~INR 2,000 crores for 1,700 beds, with 1,500 beds as brownfield and 200 as greenfield.
  • Per bed capex estimate: INR 0.8-1.1 crores for brownfield and INR 1.5-1.6 crores for greenfield projects.
  • Recent expansions include operationalizing Whitefield Block D with 159 beds and Ramesh Sanghamitra Ongole with 75 beds in April 2026.
  • Capex spend guidance maintained at around 5% of revenue for maintenance and clinical program refreshers.

2 more points from Aster DM Quality's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aster DM Quality said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • QCIL has an expansion budget of around INR 2000 crores for approximately 1700 beds, with about 1500 beds being brownfield expansions.
  • The blended per bed capex for the QCIL expansion is roughly INR 1-1.1 crores, varying by hospital and specialty.
  • Aster DM Healthcare plans to add around 2,500 beds over the next four years at a cost of INR 2700 crores.
  • Of this INR 2700 crores, INR 350 crores has already been invested up to March 2026; the remaining amount will be deployed over the next 3-4 years.

2 more points from Aster DM Quality's call on order book

Create a free account to keep reading this call

Aster DM Quality — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aster DM Quality Q4 FY26 results — key figures

Aster DM Quality Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,1821,000+18.2%1,186-0.3%
Operating profit (EBITDA)224182+23.1%202+10.9%
Operating margin19%18%+1 pp17%+2 pp
Profit before tax16391+79.1%103+58.3%
Net profit (PAT)15486+79.1%59+161%
EPS (₹)2.711.58+71.5%1.01+168.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹322 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aster DM Quality and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aster DM Quality Q4 FY26 results?

QCIL registered 17% revenue growth in FY26, supported by 7% IP volume and 10% OP volume growth. QCIL expects continued growth with FY26 registering 17% revenue growth and 24.1% EBITDA growth, indicating strong momentum.

What is Aster DM Quality share price analysis?

Aster DM Quality currently shows a neutral. The stock trades at a P/E of 183.9 with a market cap of ₹66,382 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aster DM Quality planning capital expenditure?

For the year ended March 31, 2026, capital expenditure was INR 549 crores, with 45% towards expansion projects.

Keep Aster DM Quality on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.